Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 23 May 2017 Status changed from active, no longer recruiting to completed.
- 08 Mar 2017 Planned End Date changed from 1 Dec 2016 to 30 Apr 2017.
- 01 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.